Healthcare Industry News: HSMN NewsFeed
News Release - December 20, 2017
Amneal Brings Generic for Renvela(R) to Market and Starts December Strong with Six Product LaunchesBRIDGEWATER, N.J., Dec. 20, 2017 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals LLC has launched sevelamer carbonate tablets, 800 mg, in 270-count bottles. The Amneal generic is an AB-rated therapeutic equivalent to Renvela®. Moving annual total U.S. sales of Renvela and its generic equivalent were $1.8 billion according to October 2017 IQVIA™ market data.
Amneal recently launched five other products in addition to sevelamer carbonate:
- Progesterone Capsules, AB-rated equivalent to Prometrium® in 100 mg and 200 mg strengths
- Bumetanide Tablets, USP, AB-rated to Bumex®, in 0.5 mg, 1 mg and 2 mg strengths
- Ezetimibe and Simvastatin Tablets, an AB-rated generic for Vytorin® in four strengths
- Clonidine HCl Extended-Release Tablets, AB1-rated to Kapvay® in 0.1 mg strength
- Triamcinolone Acetonide Injectable Suspension, USP in 40 mg/mL strength
"Our approval and launch of sevelamer carbonate tablets is yet another example of Amneal's commitment to successfully provide complex pharmaceutical products to the US market," said Jim Luce, Amneal Executive Vice President, Sales & Marketing. "Our pipeline continues to grow with more than 132 ANDAs filed and another 140 in development."
Please see full safety and prescribing information including boxed warning for:
Amneal Pharmaceuticals LLC, a privately-held company headquartered in Bridgewater, New Jersey, is one of the largest and the fastest growing generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now has more than 5,000 employees in North America, Asia and Europe, working together to bring high-quality affordable medicines to patients worldwide. Amneal has significantly expanded its portfolio of generic products to include complex dosage forms in a broad range of therapeutic areas. For more information, visit www.amneal.com.
All trademarks listed in this release are property of their respective owners.
Source: Amneal Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAmneal Announces Favorable Ruling Regarding Patent Validity for Zomig(R) (zolmitriptan) Nasal Spray
Amneal Announces Patent Litigation Settlement Agreement with Actavis Concerning Rytary(R)
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States